Mucosal Immunity
34.5K views | +21 today
Mucosal Immunity
The largest immune tissue in the body
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
April 29, 2022 11:53 AM
Scoop.it!

Lars Å. (Nenne) Hanson (1934–2022): A Retrospective | Mucosal Immunology

Lars Å. (Nenne) Hanson (1934–2022): A Retrospective | Mucosal Immunology | Mucosal Immunity | Scoop.it

You have full access to this article via your institution.

Gilbert C FAURE's insight:

before IgA in mucosal immunity and before milk return

No comment yet.
Scooped by Gilbert C FAURE
April 23, 2022 3:13 AM
Scoop.it!

Trophoblast antigens, fetal blood cell antigens, and the paradox of fetomaternal tolerance | Journal of Experimental Medicine | Rockefeller University Press

We review our current understanding of adaptive immune responses to the fetoplacental allograft, emphasizing the divergent responses observed for trophoblast- v
No comment yet.
Scooped by Gilbert C FAURE
April 13, 2022 1:48 PM
Scoop.it!

Frontiers | miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease | Immunology

Frontiers | miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease | Immunology | Mucosal Immunity | Scoop.it
The most obvious pathological characterization of inflammatory bowel disease (IBD) is intestinal epithelium erosion and severe inflammation invasion. Micro-ribonucleic acids (miRNA or microRNA), single-stranded noncoding RNAs of ~22 nucleotides, have been considered as the potential therapeutic targets in the pathogenesis of IBD. Many previous studies have focused on the mechanisms that miRNAs use to regulate inflammation, immunity, and microorganisms in IBD. The review highlights in detail the findings of miRNAs in the intestinal epithelial barrier of IBD, and focuses on their gene targets, signaling pathways associated with IBD, and some potential therapies. It will be beneficial for the elucidation of the interaction between miRNAs and the intestinal epithelial barrier in IBD and provide a theoretical reference for preventing and treating IBD in the future.
No comment yet.
Scooped by Gilbert C FAURE
April 13, 2022 4:53 AM
Scoop.it!

Expelliarmus helminthus! Harry Helminth and the Goblet of Alarmins

Expelliarmus helminthus! Harry Helminth and the Goblet of Alarmins | Mucosal Immunity | Scoop.it
Epithelial cells (tuft and goblet cells) interact with immune cells on the “inside”
while secreting effector molecules into the topological “outside.” In this issue of
Immunity, Zhao et al. investigate an interleukin-33 (IL-33) secretion mechanism in
goblet cells dependent on O-GlcNAcylation and gasdermin pores facilitating worm expulsion.
No comment yet.
Scooped by Gilbert C FAURE
April 11, 2022 2:02 PM
Scoop.it!

An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications

An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications | Mucosal Immunity | Scoop.it
Prevalence of autoimmune diseases is increasing around the world. As a result, modern society is strongly impacted by a social and economic burden.Given the unique characteristics of celiac disease, a better understanding of its pathogenesis and the factors that contribute to it may shed light on...
No comment yet.
Scooped by Gilbert C FAURE
April 8, 2022 4:34 AM
Scoop.it!

Frontiers | Cytokine-Mediated Crosstalk Between Keratinocytes and T Cells in Atopic Dermatitis | Immunology

Frontiers | Cytokine-Mediated Crosstalk Between Keratinocytes and T Cells in Atopic Dermatitis | Immunology | Mucosal Immunity | Scoop.it
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by barrier dysfunction, dysregulated immune response, and dysbiosis with increased Staphylococcus aureus colonization. Infiltration of various T helper cell subsets into lesional skin and subsequent cytokine release are a hallmark of AD. Release of cytokines by both T cells and keratinocytes plays a key role in skin inflammation and drives many AD features. This review aims to discuss cytokine-mediated crosstalk between T cells and keratinocytes in AD pathogenesis and the potential impact of virulence factors produced by Staphylococcus aureus on these interactions.
No comment yet.
Scooped by Gilbert C FAURE
March 27, 2022 4:57 AM
Scoop.it!

GVHD, IBD and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunity

GVHD, IBD and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunity | Mucosal Immunity | Scoop.it
The intestinal tract is the largest immunological organ in the body and has a central function of regulating local immune responses, as the intestinal epithelial barrier is a location where the immune system interacts with the gut microbiome including bacteria, fungi and viruses.
No comment yet.
Scooped by Gilbert C FAURE
March 4, 2022 1:00 PM
Scoop.it!

Des chercheurs chinois développent un anticorps inhalable contre la COVID-19 et ses variants — Chine Informations

Des chercheurs chinois développent un anticorps inhalable contre la COVID-19 et ses variants — Chine Informations | Mucosal Immunity | Scoop.it
Alors que le monde attend des thérapies efficaces contre la COVID-19, des chercheurs de l'Académie chinoise des sciences affirment avoir mis au point un...
No comment yet.
Scooped by Gilbert C FAURE
March 3, 2022 2:32 AM
Scoop.it!

Immune memory in the intestine: new insights into “innate memory” | Immunopaedia

Immune memory in the intestine: new insights into “innate memory” | Immunopaedia | Mucosal Immunity | Scoop.it
02 March 2022 In a recent paper, Serafinain, et al., have made us of an intestinal infection model to discover that group 3 innate lymphoid cells (cells of the innate immune system) may also develop an innate form of immunologica
No comment yet.
Scooped by Gilbert C FAURE
March 2, 2022 4:37 AM
Scoop.it!

Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller | Journal of Experimental Medicine | Rockefeller University Press

This study identifies a trio of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a HIV-1 viremic controller that all target a unique viral site of vu
No comment yet.
Scooped by Gilbert C FAURE
February 25, 2022 10:52 AM
Scoop.it!

IJMS | Free Full-Text | The Human Microbiota and Skin Cancer

IJMS | Free Full-Text | The Human Microbiota and Skin Cancer | Mucosal Immunity | Scoop.it
Skin cancer is the most common type of cancer in the US with an increasing prevalence worldwide. While ultraviolet (UV) radiation is a well-known risk factor, there is emerging evidence that the microbiota may also contribute. In recent years, the human microbiota has become a topic of great interest, and its association with inflammatory skin diseases (i.e., atopic dermatitis, acne, rosacea) has been explored. Little is known of the role of microbiota in skin cancer, but with the recognized link between microbial dysbiosis and inflammation, and knowledge that microbiota modulates the effect of UV-induced immunosuppression, theories connecting the two have surfaced. In this paper, we provide a comprehensive review of the key literature on human microbiota, especially the skin microbiota, and skin cancer (i.e., non-melanoma skin cancer, melanoma, cutaneous T cell lymphoma). Also, mechanistic perspectives as to how our microbiota influence skin cancer development and treatment are offered.
No comment yet.
Scooped by Gilbert C FAURE
February 21, 2022 6:15 AM
Scoop.it!

Bacteria-Infecting Viruses in Gut Microbiome Linked to Cognition

Bacteria-Infecting Viruses in Gut Microbiome Linked to Cognition | Mucosal Immunity | Scoop.it
Research in mice and flies suggests that bacteriophages, including those found in dairy foods, may have an influence on an animals’ ability to learn and remember information.
No comment yet.
Scooped by Gilbert C FAURE
April 26, 2022 1:52 PM
Scoop.it!

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection | Mucosal Immunology

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection | Mucosal Immunology | Mucosal Immunity | Scoop.it
Although SARS-CoV-2 infects the upper respiratory tract, we know little about the amount, type, and kinetics of antibodies (Ab) generated in the oral cavity in response to COVID-19 vaccination. We collected serum and saliva samples from participants receiving two doses of mRNA COVID-19 vaccines and measured the level of anti-SARS-CoV-2 Ab. We detected anti-Spike and anti-Receptor Binding Domain (RBD) IgG and IgA, as well as anti-Spike/RBD associated secretory component in the saliva of most participants after dose 1. Administration of a second dose of mRNA boosted the IgG but not the IgA response, with only 30% of participants remaining positive for IgA at this timepoint. At 6 months post-dose 2, these participants exhibited diminished anti-Spike/RBD IgG levels, although secretory component-associated anti-Spike Ab were more stable. Examining two prospective cohorts we found that participants who experienced breakthrough infections with SARS-CoV-2 variants had lower levels of vaccine-induced serum anti-Spike/RBD IgA at 2–4 weeks post-dose 2 compared to participants who did not experience an infection, whereas IgG levels were comparable between groups. These data suggest that COVID-19 vaccines that elicit a durable IgA response may have utility in preventing infection. Our study finds that a local secretory component-associated IgA response is induced by COVID-19 mRNA vaccination that persists in some, but not all participants. The serum and saliva IgA response modestly correlate at 2–4 weeks post-dose 2. Of note, levels of anti-Spike serum IgA (but not IgG) at this timepoint are lower in participants who subsequently become infected with SARS-CoV-2. As new surges of SARS-CoV-2 variants arise, developing COVID-19 booster shots that provoke high levels of IgA has the potential to reduce person-to-person transmission.
No comment yet.
Scooped by Gilbert C FAURE
April 22, 2022 11:41 AM
Scoop.it!

Frontiers | Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut | Immunology

Frontiers | Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut | Immunology | Mucosal Immunity | Scoop.it
Initially known as a cytokine produced by and regulating the function of monocytes and macrophages, interleukin-34 (IL-34) can be synthesized by many cell types and interacts with receptors expressed by multiple immune and non-immune cells. IL-34 is constitutively expressed in the healthy human small intestine and colon and its production is markedly increased in damaged gut of patients with Crohn’s disease and patients with ulcerative colitis, the main forms of chronic inflammatory bowel diseases (IBD) in human beings. Circumstantial evidence suggests that, in these pathologies, IL-34 plays a crucial role in mediating cross-talk between immune cells and stromal cells, thereby promoting activation of signalling pathways, which amplify the ongoing mucosal inflammation as well as production of fibrogenic molecules. In this article, we summarize the available data supporting the multiple effects of IL-34 in human IBD with particular attention to the role of the cytokine in immune and stromal cell interactions.
No comment yet.
Scooped by Gilbert C FAURE
April 13, 2022 5:44 AM
Scoop.it!

Intestinal Tuft-2 cells exert antimicrobial immunity via sensing bacterial metabolite N-undecanoylglycine

Intestinal Tuft-2 cells exert antimicrobial immunity via sensing bacterial metabolite N-undecanoylglycine | Mucosal Immunity | Scoop.it
Tuft cells play a critical role in immunity against parasite infection, but whether
Tuft cells participate in bacterial eradication is presently unclear. Xiong et al.
reveal that Tuft-2 cells mediate immunity against bacterial infection through Vmn2r26-mediated
recognition of bacterial metabolites.
No comment yet.
Scooped by Gilbert C FAURE
April 13, 2022 4:52 AM
Scoop.it!

https://www.sciencedirect.com/science/article/pii/S1074761322001388?dgcid=author

No comment yet.
Scooped by Gilbert C FAURE
April 9, 2022 5:23 AM
Scoop.it!

Human enteric viruses autonomously shape inflammatory bowel disease phenotype through divergent innate immunomodulation

No comment yet.
Scooped by Gilbert C FAURE
March 29, 2022 3:37 AM
Scoop.it!

JCI - Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier

JCI - Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier | Mucosal Immunity | Scoop.it
This study included biospecimens from 100 children: 19 children were clinically diagnosed with MIS-C as defined by CDC criteria (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI149633DS1); 26 children had COVID-19 confirmed by RT-PCR; and 55 children served as non–COVID-19 controls (32 pre-pandemic). The average age of the children with MIS-C (8 years old) was younger than that of the children who presented with COVID-19 (14 years old), which is consistent with the national averages (2, 15). The patients with MIS-C presented with a median of 3 days of acute symptoms associated with MIS-C (range, 1–28 days), after a previous COVID-19 exposure or SARS-CoV-2 infection 26 days prior to the presentation with MIS-C (range, 13–62 days). Notably, GI symptoms were predominant in the MIS-C cohort, affecting 89% of these patients, compared with 27% of children with acute COVID-19 (Fisher’s exact test, P < 0.0001; Table 1). Figure 1 outlines the specimens collected for the analysis and the timing of specimen collection from the children with MIS-C or acute COVID-19. Figure 1Study overview. Timing of sample collection and sample analysis for children with MIS-C or acute COVID-19. Table 1Age and sex for all pediatric patients and controls, and clinical features of illness for the children with acute COVID-19 or MIS-C SARS-CoV-2 in the GI tract of children with MIS-C coincides with a loss of intestinal epithelial barrier function. MIS-C develops several weeks after a SARS-CoV-2 infection or exposure (Table 1), and the viral load in respiratory secretions is known to decrease over the course of 7–10 days after infection (11, 16, 17). As most children with MIS-C have negative nasopharyngeal viral swabs (11), MIS-C is unlikely to be related to this initial infection of the respiratory tract. To assess the presence of SARS-CoV-2 in the GI tract, we measured SARS-CoV-2 RNA from MIS-C stool samples collected several weeks after the initial SARS-CoV-2 infection or exposure. Indeed, a majority of the patients showed detectable viral loads in the stool ranging from 1.5 × 102 to 2.5 × 107 RNA copies/mL, suggesting an ongoing nidus of infection in MIS-C (Supplemental Table 1). An intact, functional intestinal mucosal barrier should prevent the passage of large antigens from the gut lumen into the bloodstream, including viral antigens derived from SARS-CoV-2 present in the GI tract (12). Zonulin belongs to a family of structurally and functionally related proteins that reversibly regulate intestinal permeability by modulating intercellular tight junctions (18–20). Increased circulating zonulin levels resulting in increased intestinal permeability have been reported in several diseases (21) including autoimmune and hyperinflammatory diseases such as celiac disease (22), inflammatory bowel disease (23), and Kawasaki disease (24). Zonulin release from epithelial cells can result in permissibility of paracellular trafficking of large inflammatory antigens from the gut lumen into the bloodstream. In this study, mass spectrometry showed that, compared with controls, children with MIS-C had significantly increased release of zonulin into the circulation (P = 0.003; Figure 2A), which can result in a breakdown of mucosal barrier function. Correspondingly, children with MIS-C also had increased LPS-binding protein (LBP) levels compared with controls (P = 0.007; Figure 2B), signaling increased microbial translocation. Levels of soluble CD14, another marker of microbial translocation, were also increased in children with MIS-C (P = 0.1; Figure 2C), indicating a loss of GI mucosal barrier integrity. None of these markers of GI barrier integrity — zonulin, LBP, or CD14 — was significantly increased in the children with acute COVID-19 infection. Identification of SARS-CoV-2 within the stool, coupled with the loss of competency of tight junctions seen in MIS-C, but not acute COVID-19, suggests that GI sources of SARS-CoV-2 viral components could breach the mucosal barrier and enter the circulation. Figure 2Plasma (A) zonulin, (B) LPS-binding protein, and (C) soluble CD14 levels were quantified by multiplexed MS–based proteomics (54, 55) for children with MIS-C (n = 13) or COVID-19 (n = 21) and for non–COVID-19 control participants (n = 23). Results were compared by ANOVA. (D) SARS-CoV-2 spike, (E) S1, and (F) nucleocapsid protein levels were quantified in plasma from children with MIS-C (n = 16), children with acute COVID-19 (n = 22), and pre-pandemic healthy controls (n = 32). Results were compared by 1-way ANOVA with multiple comparisons. * P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Median values and 95% CI are presented. Children with MIS-C have SARS-CoV-2 antigenemia. Although viremia and antigenemia have been shown to correlate with severe acute COVID-19 in adults (17, 25), viremia has not been detected in MIS-C (11), and antigenemia has not previously been assessed in children. Using single-molecule array (Simoa) assays (25), we detected SARS-CoV-2 spike, S1, and nucleocapsid antigens in the plasma of children with MIS-C despite being weeks past their initial SARS-CoV-2 infection or exposure. The SARS-CoV-2 spike protein was significantly elevated in patients with MIS-C compared with healthy controls (P < 0.0001) and compared with children with acute COVID-19 (P < 0.001; Figure 2D). We also detected the SARS-CoV-2 S1 protein at significantly elevated levels in patients with MIS-C compared with healthy controls (P = 0.004) and with children with acute COVID-19 (P = 0.02; Figure 2E). SARS-CoV-2 nucleocapsid protein levels were increased in patients with MIS-C, although these levels did not reach significance (Figure 2F). We detected no significant increase in SARS-CoV-2 antigenemia in children with acute COVID-19 as compared with healthy controls. SARS-CoV-2 antigens showed no correlation with age (Supplemental Figure 1). Circulating SARS-CoV-2 antigen indicates that viral components have leaked from infected tissues. We attribute circulating antigen in patients with MIS-C to leakage from the GI system, as corroborated by the increased zonulin levels and microbial translocation markers we detected in the patients with MIS-C. The SARS-CoV-2 spike protein, specifically the S1 component (9, 10), has been hypothesized to have superantigen-like properties that are similar to those seen in the bacterial superantigen–mediated toxic shock syndrome. Superantigens bind to specific β-chains of T cell receptors (TCRs) at the variable domain in a complementary-determining region 3–independent (CDR3-independent) manner (26), thereby bypassing TCR specificity and resulting in skewing and overrepresentation of specific TCRs. Recent reports have identified TCR β variable (TRBV) gene skewing in MIS-C, with a profound expansion of TRBV11-2 (10, 27). Our data reveal a strong correlation between S1 antigenemia and the previously reported expression of TRBV11-2 in MIS-C (ref. 10; Pearson’s correlation, r = 0.89, P = 0.0005; Supplemental Figure 2). We found no correlation between the spike or nucleocapsid antigens and TRBV11-2 expression (Supplemental Figure 2). Consistent with hyperinflammatory responses, children with MIS-C experienced a cytokine storm with significantly elevated levels of IL-1β, IL-6, IL-10, and TNF-α (Supplemental Figure 3, A–D). Notably, the antiviral cytokine IFN-γ was also significantly increased in patients with MIS-C compared with both healthy controls and children with acute COVID-19 (Supplemental Figure 3E). This increase in IFN-γ is typical of a viral exposure, however, it can be paradoxically suppressed in adults with severe acute COVID-19 (28). We also assessed IL-12p70, IL-8, IL-5, and IL-22 levels but found that they were not altered in the children with MIS-C or acute COVID-19 (Supplemental Figure 3, F–I). MIS-C immunoprofiles reflect ongoing mucosal exposure to SARS-CoV-2. The immunoglobulin IgM, IgG, and IgA subsets targeting SARS-CoV-2 antigens in patients with MIS-C were most highly elevated against spike and S1 proteins (Figure 3, A–C, and Supplemental Figure 4), corresponding to the antigens most highly detected in the bloodstream of these children. As expected, anti–spike IgM was highest in children with acute COVID-19, reflecting early adaptive immune responses (Figure 3A). However, anti–spike IgM levels remained higher than would be expected, given that MIS-C presents weeks after the original infection with or exposure to SARS-CoV-2, but was on a downward trend over time (Figure 3D). As expected, anti–spike IgG, anti–S1 IgG, and anti–RBD IgG were highest in the children with delayed-onset MIS-C (Figure 3B and Supplemental Figure 4) and remained plateaued over time (Figure 3E). IgA is the immunoglobulin most reflective of mucosal immunity and typically wanes following viral clearance (29). Here, the levels of anti–spike IgA, anti–S1 IgA, and anti–RBD IgA were all significantly increased in the patients with MIS-C (Figure 3C and Supplemental Figure 4), and anti–spike IgA remained unexpectedly elevated for months after the initial SARS-CoV-2 infection (Figure 3F). The persistence of elevated anti–SARS-CoV-2 IgA and IgM in patients with MIS-C supports the hypothesis of ongoing viral antigenic exposure and inflammation in the GI mucosal surfaces of children with MIS-C. Figure 3Peak values of (A) anti–spike IgM, (B) anti–spike IgG, and (C) anti–spike IgA were quantified in plasma from children with MIS-C (n = 16), children with acute COVID-19 (n = 22), and pre-pandemic healthy controls (n = 32). Results were compared by 1-way ANOVA with multiple comparisons. Time course of (D) anti–spike IgM, (E) anti–spike IgG, and (F) anti–spike IgA were plotted over time following symptom onset for MIS-C. (G) The IC50 for antibody neutralization for children with MIS-C and children with acute COVID-19 were compared by Mann-Whitney t test. Mean values and the SD are presented. *P < 0.05, **P < 0.01, and ****P < 0.0001. We compared the capacity of plasma neutralization against SARS-CoV-2 between children with MIS-C and those with acute COVID-19. Interestingly, although the children with MIS-C had significantly elevated IgG antibody titers against SARS-CoV-2 relative to those with acute COVID-19, the neutralization titers were comparable between the children from both groups (Figure 3G). This suggests that in children with MIS-C, increasing quantities of IgG antibodies against the SARS-CoV-2 spike protein did not result in a gain in neutralizing capacity over time. Ineffective neutralization and poor antigen clearance, combined with ongoing viral antigen leakage from GI sources, could partially explain the high levels of antigen detected in the children with MIS-C. Temporal kinetics reveal that SARS-CoV-2 antigenemia is inadequately contained by humoral responses in MIS-C. Both SARS-CoV-2 antigen and immunoglobulins were detectable in patients with MIS-C at levels significantly higher than those detected in healthy controls. Antigenemia in adults occurs early in the COVID-19 disease course and is associated with pulmonary symptoms (25), whereas in MIS-C, antigenemia is found in the setting of prominent GI symptoms weeks to months after resolution of a SARS-CoV-2 upper respiratory tract infection or asymptomatic infection. To understand the relationship between viral antigenemia and the humoral response, we studied longitudinal samples from patients with MIS-C. First, we assessed antigens over time following MIS-C symptom onset. Previous reports show that in adults with acute COVID-19, SARS-CoV-2 antigens are rapidly cleared as the patient reaches seroconversion (25, 30). In contrast, our studies showed that spike antigens rose over the first few days of MIS-C symptoms and persisted for more than 10 days, occasionally through 6 months (Supplemental Figure 5), despite seroconversion to anti–spike IgG and anti–spike IgA antibodies. The elevated presence of spike protein in seroconverted patients was not observed in any adult COVID-19 cases (25). We also found that SARS-CoV-2 antigen levels did not significantly decrease in our cohort following the initiation of steroid and/or intravenous immunoglobulin (IVIG) replacement therapy (Figure 4A), which are the only currently recommended treatments for MIS-C (31). This suggests that current therapies are targeted toward the downstream consequences of MIS-C, namely the inflammatory responses, but fail to address the ongoing antigenemia instigating ongoing inflammation. Figure 4B provides a detailed overview of spike antigenemia and the humoral inflammatory responses in a representative hospitalized child with MIS-C, relative to SARS-CoV-2 exposure, symptom onset, and treatment course. Figure 4(A) SARS-CoV-2 spike, S1, and nucleocapsid levels in plasma from children with MIS-C were quantified before treatment with steroids and/or immunoglobulin replacement therapy, through 14 days following treatment (n = 11). Shaded regions signify the limit of detection for each specific antigen test. (B) Spike and anti–spike IgM, anti–spike IgG, and anti–spike IgA levels were measured over the course of illness of a child with MIS-C. Of note, the spike protein remained above the limit of detection for the spike antigen test at the 213-day follow-up point. Zonulin antagonism reduces spike antigenemia and cytokine storm, with subsequent improvement in clinical outcomes in MIS-C. Although steroids and IVIG do not block leakage of SARS-CoV-2 antigen across the mucosal barrier, therapies targeting GI mucosal permeability could potentially reduce or prevent antigenemia. Larazotide, a zonulin antagonist, is an investigational therapy that has been well characterized in preclinical trials (32, 33), with an excellent safety profile (34), and is currently in phase III trials for the treatment of refractory celiac disease (35). Given this theoretical benefit, we obtained US FDA approval for compassionate use of larazotide, 10 μg/kg every 6 hours, to treat a critically ill 17-month-old boy with MIS-C after he failed to improve with antiinflammatory therapies. The toddler, who had a complex past medical history including partial duplication of chromosome 14, biliary atresia status post Kasai procedure, and gastrotomy tube placement, with frequent episodes of ascending cholangitis, required hospitalization for severe COVID-19, complicated by respiratory failure and cardiac resuscitation. One month after he was diagnosed with COVID-19, he developed abdominal compartment syndrome with a C-reactive protein (CRP) level of 286 mg/L, a ferritin level of 51,223 μg/L, and a N-terminal pro-b–type natriuretic peptide (NT-proBNP) level of 16,462 pg/mL without evidence of cardiac injury on echocardiogram. He was treated with IVIG, steroids, and anakinra with transient improvement of inflammatory markers but rapid recrudescence of symptoms. We detected 1020 copies of SARS-CoV-2 RNA in the patient’s stool, as quantified by RT-PCR, and a plasma spike antigen level of 566 pg/mL more than 2 weeks after initiation of IVIG and steroid treatment for MIS-C. After the initiation of larazotide, his CRP level, which had quickly rebounded to 173 mg/L following withdrawal of anakinra, dropped by 85% from peak values, and spike antigen levels dropped by 90% to 59 pg/mL (Figure 5A). The SARS-CoV-2 nucleocapsid protein levels also dropped by 98% from 77 pg/mL to 1.45 pg/mL (limit of detection). His fever curve, which also rebounded after discontinuation of anakinra, improved, as did his ferritin and D-dimer levels (Figure 5A). The patient also experienced an improvement in cytokine and inflammatory mediator levels, including IL-1β, IFN-γ, IL-2R, and IL-17, representing an improvement in inflammasome activation, virus-induced IFN release, and immune cell activation (Figure 5B). These cytokines and inflammatory mediators initially spiked during the development of MIS-C, then improved following IVIG but plateaued or rebounded despite steroid treatment. We observed an improvement in these inflammatory mediators following the precipitous drop in SARS-CoV-2 antigens, which occurred as a result of or coincident with the initiation of larazotide therapy. Importantly, the patient achieved his longest stretches without fever since his hospital admission, his GI symptoms improved and he was able to resume full feedings, and his ventilatory status improved. Figure 5Timeline for the child treated with larazotide. The hospital course is delineated by hospitalization for acute COVID-19 (day 0) followed by development of MIS-C (day 39), with the treatment courses identified along the time course. (A) CRP and SARS-CoV-2 spike antigen levels, the median daily temperature (temp) curve, and D-dimer and ferritin levels throughout the hospital course are shown. Light blue shading represents a normal body temperature. The light gray shading highlights the days of larazotide treatment. (B) Inflammatory cytokine IL-17F, IL-2R, IFN-γ, and IL-1β levels following the development of MIS-C, in relation to the treatment courses.
No comment yet.
Suggested by LIGHTING
March 26, 2022 5:34 AM
Scoop.it!

Measles Virus - an overview | ScienceDirect Topics

Measles Virus - an overview | ScienceDirect Topics | Mucosal Immunity | Scoop.it
Measles VirusMeasles virus (MV) binds to cell surface receptors by way of its hemagglutinin (H) protein to initiate infection.From: xPharm: The Comprehensive Pharmacology Reference, 2007Related terms:Subacute Sclerosing PanencephalitisVaccine EfficacyCD46Monospecific AntibodyParamyxoviridaeImmunityWild TypeHuman Immunodeficiency VirusView all TopicsMeasles VirusR. Cattaneo, M. McChesney, in Encyclopedia of Virology (Third Edition), 2008Measles virus (MV), one of the most contagious viruses known, was recognized clinically by the rash and other signs from early historical times. Measles still causes more than 300 000 deaths each year, mostly due to secondary infections facilitated by MV-induced immunosuppression. Therefore the World Health Organization has targeted it for eradication, an endeavor facilitated by the availability of a live attenuated vaccine with an outstanding efficacy and safety record. MV is an enveloped negative-strand RNA virus, and the study of its biology has given detailed insights about how it utilizes host cell components to promote its replication and particle assembly. Moreover, the MV interactions with the cellular receptors and the mechanisms used to invade and inactivate the host immune system are now better understood. The knowledge gained from basic research is currently used to develop multivalent MV-based vaccines, and vectors for targeting and eliminating cancer cells.View chapterPurchase bookRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B978012374410400443XDevelopmental Aspects of Pagetic OsteoclastsDeborah L. Galson, ... G. David Roodman, in Advances in Pathobiology and Management of Paget's Disease of Bone, 2016MVNP Downregulation of FoxO3 and Sirt1 also Increase IL-6MVNP also was demonstrated to increase NFκB activity by downregulating expression of Sirtuin 1 (Sirt1), a class III protein deacetylase that targets acetylated NFκB and negatively regulates its activity [31]. MVNP decreases Sirt1 by triggering increased phosphorylation of Forkhead-box class O3 (FoxO3), resulting in decreased FoxO3 protein stability and decreased transcription of its target gene Sirt1 in OCL precursors and NIH3T3 cells. Several protein kinases have been reported to downregulate FoxO3 stability through phosphorylation, including AKT, ERK1/2, IKKβ, and IKKε [50–52]. It’s not yet known which, if any, of these are triggered by MVNP to phosphorylate FoxO3. However, TBK1 overexpression in TRAP-TBK1 BMM was sufficient to decrease Sirt1 mRNA (unpublished data), suggesting that activated TBK1 may phosphorylate FoxO3. Wang et al. [31] showed that NIH3T3 cells stably transduced with MVNP (MVNP-NIH3T3) demonstrated higher IL-6 promoter luciferase reporter activity than NIH3T3 cells transduced with empty vector (EV-NIH3T3), and ectopic expression of Sirt1 significantly decreased both the basal and MVNP-stimulated IL-6 promoter activity. Further, resveratrol, a Sirt1 gene activator, suppressed the high level of IL-6 mRNA in MVNP-NIH3T3 cells. Significantly, resveratrol inhibited OCL differentiation of BMM from both wild-type and MVNP mice. Strikingly, at a resveratrol dose that had little effect on wild-type OCL differentiation, the enhanced MVNP OCL differentiation was suppressed to wild-type levels. Higher resveratrol doses then suppressed wild-type and MVNP OCL differentiation to similar levels. Hence, MVNP acts via two pathways to increase IL-6 expression (Fig. 4.2).View chapterPurchase bookRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B978012805083500004XNeurovirologyJane E. Libbey, Robert S. Fujinami, in Handbook of Clinical Neurology, 2014Measles virusMeasles virus (Chapter 27) is a Morbillivirus, of the family Paramyxoviridae, and is an enveloped single-stranded negative-sense RNA virus (Nathanson and Gonzalez-Scarano, 2007). Measles virus is spread by the respiratory route (Nathanson and Gonzalez-Scarano, 2007). One neurologic complication of measles virus infection, thought to be related to dysregulation of the cellular immune responses, as it can occur in the absence of viral replication in the CNS, is postinfectious encephalomyelitis, which develops within weeks of infection (Johnson et al., 1983, 1984; Hirsch et al., 1984; Johnson, 1987). However, measles virus can infect and persist in neurons (Parra et al., 1999; Ramakrishna et al., 2002). In immunocompetent individuals a CD4 + T-cell population mediates elimination of measles virus from neurons, possibly through secretion of IFN-γ (Parra et al., 1999; Schneider-Schaulies et al., 2003). Failure of the immune response to eliminate measles virus-infected cells completely from the CNS can result in viral persistence (Schneider-Schaulies et al., 1999).Measles virus is capable of persisting in neurons as a defective variant that spreads from neuron to neuron directly, without passage through the extracellular environment (Schneider-Schaulies et al., 1999, 2003; Lawrence et al., 2000; Nathanson and Gonzalez-Scarano, 2007). In this way the virus avoids detection and elimination by circulating high titers of measles virus-specific neutralizing antibody. The persistence of measles virus in the CNS can result in a progressive fatal encephalitis called SSPE developing in immunocompetent individuals several months to years after infection and recovery from acute measles virus infection (Schneider-Schaulies et al., 1999, 2003; Nathanson and Gonzalez-Scarano, 2007). As such, SSPE is primarily a disease of childhood and young adulthood (Gilden, 1983; Wolinsky, 1990).As described above, oligoclonal IgG antibody bands, with measles virus-restricted specificities, are characteristically found in the serum and CSF of patients with SSPE (Mehta et al., 1994; Burgoon et al., 2006; Tschen et al., 2006). These oligoclonal bands are a hyperimmune response to measles virus antigens, which, despite their neutralizing activity, are unable to control the viral infection (Mehta et al., 1994). This inability of measles virus-specific antibodies to control measles virus infection in SSPE patients may result from antibody-induced antigenic modulation by the virus (Fujinami and Oldstone, 1980, 1983; Fujinami et al., 1984). The expression of some measles virus antigens within and on the surface of measles virus-infected cells is altered upon binding of measles virus-specific antibodies such that the synthesis, assembly, and maturation of the virions are altered. In this way the measles virus-infected cells may avoid detection and lysis and measles virus may persist. Thus, in the case of measles virus, the antibody arm of the adaptive immune response to the virus may play a role in the initiation of viral persistence (Fujinami and Oldstone, 1980, 1983; Fujinami et al., 1984).View chapterPurchase bookRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B9780444534880000109MeaslesWilliam J. Moss, in Tropical Dermatology (Second Edition), 2017Natural History, Pathogenesis, and PathologyMeasles virus is primarily transmitted by respiratory droplets over short distances and, less commonly, by small-particle aerosols that remain suspended in the air for long periods of time. The time from infection to clinical disease is approximately 10 days to the onset of fever and 14 days to the onset of rash. Persons with measles are infectious for several days before and after the onset of rash, when levels of measles virus in blood and body fluids are highest and when the symptoms of cough, coryza, and sneezing are most severe. The host immune response at sites of virus replication is responsible for the signs and symptoms of measles.Host immune responses to measles virus are essential for viral clearance, clinical recovery, and the establishment of long-term immunity.7 The protective efficacy of antibodies to measles virus is illustrated by the immunity conferred to infants from passively acquired maternal antibodies and the protection of exposed, susceptible individuals following administration of anti-measles-virus immunoglobulin. The duration of protective immunity following wild-type measles virus infection is generally lifelong.8 The immune responses to measles virus infection are associated with depressed responses to unrelated (non-measles-virus) antigens lasting for several weeks to months. This state of immune suppression enhances susceptibility to secondary bacterial and viral infections causing pneumonia and diarrhea, and is likely responsible for much of measles-associated morbidity and mortality.9 Vitamin A deficiency is a recognized risk factor for severe measles. The vitamin is essential for the maintenance of normal epithelial tissues throughout the body; measles virus itself infects and damages these tissues.View chapterPurchase bookRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B9780323296342000146Measles Virus (Rubeola)Anne A. Gershon, in Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition), 2015Growth of Measles Virus in Tissue CultureMeasles virus was first successfully isolated in the laboratory by Enders and Peebles in 1954.18 The virus was initially propagated in primary human renal cells but later was cultivated in cultured simian kidney cells. Wild-type measles virus is rather difficult to propagate in vitro because it is slow growing, and only a limited number of types of cell cultures are permissive for the virus.16 Typically, cytopathic effects produced by measles virus in tissue cultures consist of stellate cells with increased refractility and, especially on passage, multinucleated syncytial giant cells containing intranuclear inclusions. In the absence of cytopathic effects, virus replication can also be detected by hemadsorption of rhesus monkey erythrocytes. Presumptive isolates of measles virus are identified by typing with monoclonal antibodies by using immunofluorescence or plaque reduction tests.3,19 Reverse-transcriptase polymerase chain reaction (RT-PCR) assays for measles virus are also available (see later).View chapterPurchase bookRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B9781455748013001624MeaslesAlpay Azap, Filiz Pehlivanoglu, in Emerging Infectious Diseases, 20142 What is the Causative Agent? (Taxonomy and Description of the Agent)Measles virus (MV) is a member of the genus Morbillivirus of the family Paramyxoviridea.4 It is an enveloped, non-segmented, single-stranded, negative-sense RNA virus. Measles virions are seen as pleomorphic spheres with a diameter of 100–250 nm on electron microscopy. Measles virus encodes at least eight structural proteins, which have letter names: F, C, H, L, M, N, P, and V. Of these proteins, H (hemagglutinin) has a role in the attachment of the virus to host cells, and F (fusion) is involved in the spread of the virus from one cell to another.4Measles virus is closely related to the viruses causing diseases in animals such as canine and phocine distemper and rinderpest viruses. It is stated that MV adapted to humans when humans first began to domesticate animals in Mesopotamia around 3000 BC.1 Today, wild MV is pathogenic only for primates.View chapterPurchase bookRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B9780124169753000261Infections that cause secondary immune deficiencyVincent Robert Bonagura, David Walter Rosenthal, in Stiehm's Immune Deficiencies (Second Edition), 2020Measles virus: temporary immunosuppressionMeasles virus (MV) continues to cause child morbidity and mortality worldwide, despite the availability and use of an effective live attenuated measles vaccine.10–14 Part of the reason why control of MV continues to be elusive is that it is highly contagious for susceptible individuals and there are difficulties with vaccine delivery. MV infection begins in the respiratory tract, spreads systemically in lymphoid, epithelial and endothelial cells, and ultimately infects multiple organs,15 causing a characteristic fever, rash, and conjunctivitis 10–14 days after respiratory infection (Fig. 49.3A and B). High fever, rhinorrhea and conjunctivitis typically precede the rash and the rash migrates from the head and neck to the hands and feet over 3–4 days. Many of these manifestations are caused by the immune response made to MV, and commonly this response clears MV in infected tissues and prevents re-infection for life (Fig. 49.3C and D). However, MV infection can cause several weeks of immune suppression after resolution in select individuals. This is the primary cause of measles-associated deaths: MV-induced secondary infection.16 Although vaccination against measles is very high in the United States, 92.7% of children aged 19–35 months were vaccinated in 2017,17 there are pockets of unvaccinated people who are susceptible to local outbreaks of measles. Since “herd immunity” is primarily effective when the vaccination rate is around 96%,18 vaccination levels below this level leave children and adults at risk for primary MV infection and secondary microbial infections.Measles was the first virus clearly identified to cause increased susceptibility to other microbial secondary infections. Most often, measles-associated deaths are caused by severe, overwhelming pneumonia and diarrhea.16 Suppression of delayed hypersensitivity has been identified in tuberculin-sensitized individuals many weeks after complete resolution of MV infection (Fig. 49.3C).19 Furthermore, several weeks after successful MV recovery, increased susceptibility to other infections has been reported, and T cell function and in vitro proliferation of T cells in response to mitogens has been shown to be markedly decreased (Fig. 49.4A and B).1,20,21 Immunosuppression occurs during a period of intense immune activation that occurs during the onset of the MV rash and anti-MV immune responses (Fig. 49.3C and D). Lymphopenia, skewing of Th2-like chemokine polarized responses, and suppression of lymphocyte proliferation have also been documented (Fig. 49.3D). MV infection causes decreases in T and B cells in the blood during the MV rash period.22–25 Altered trafficking and increased apoptosis of MV-infected and uninfected lymphocytes contribute to the development of lymphopenia.22,26–30 While lymphocyte numbers rapidly return to normal in the blood after the rash resolves, immunologic abnormalities persist.21,22,31,32 Immune suppression, Th2 cytokine polarization of CD4+ T cells, and Treg induction have been associated with indirect immunosuppression caused by MV infection.33,34 MV infection is also associated with suppression of IL-12 expression, lymphocyte CD30 expression, and IL-4, IL-10, and IL-13 expression after rash resolution.35–37 Reduction of IL-12 production reduces T cell expression of type I cytokines, particularly IFN-γ10,32 (Fig. 49.3D). It is possible that MV interacts with the complement regulatory molecule CD46 in polarizing Th2-like cytokine production, causing activation of signaling cascades that modify cell function, although this interaction is not firmly established.38,39 The MV-CD46 interaction may alter innate immunity by selectively downregulating receptor expression.40–46 This would increase susceptibility to complement-mediated lysis of MV-infected cells, and decrease antigen presenting cell production of IL-1247,48 and crosslinking of CD46 on T cells, leading to the induction of regulatory CD4+ T cells and enhanced IL-10 levels.49 These interactions would induce Th2-like polarization that would favor B cell maturation, provide lifelong MV antibody memory, and protect against MV re-infection. This polarization, however, would also depress APC activation and Th1-like responses to new pathogens.MV suppresses PBMC proliferation to mitogens after MV resolution, and this continues for several weeks (Fig. 49.4B).20,31 IL-2 supplementation can improve, but not fully restore, this responsiveness. This suggests that defective IL-2 expression is in part responsible for this proliferative defect.50 Cell cycle arrest in G1 after in vitro infection with MV is a recognized cause of hyporesponsiveness to mitogens.42,51–53 MV RNA can persist in PBMCs for months after MV resolution54,55 and may reduce mitogen proliferation, although this has not been established. The receptor used by wild-type MV to infect cells, CD150, is a dual function co-receptor for lymphocyte activation, and enhances IFN-γ expression.56–58 However, MV binding to CD150 can also downregulate receptor expression.59,60 T cell signaling through the MV glycoprotein complex of H and F1-F2 in the membranes of virions or MV-infected cells61–65 may also contribute to immunosuppression. This inhibitory signal prevents T cell S-phase entry for several days, and is independent of cell death, membrane fusion, soluble inhibitor production, or T cell infection.52,61,62,65–67 Thus, there is a delay in cell cycle progression and an accumulation of T cells in the G0/G1 phase.52,66,67 The mechanism by which H/F1-F2 suppresses mitogen-induced proliferation is unknown, but it is associated with MV-induced interference of T cell activation of phosphoinositide 3-kinase (PI3K) in T cells, or IL-2 receptor ligation.68 IL-2 added to MV-treated cells activates signal transducer and activator of transcription 3 (STAT3) but fails to activate Akt kinase, which is required for cell cycle progression.69 The modulatory effects of MV with glycoprotein complexes, and the downstream consequences of this interaction, have recently been summarized.10,68–70 While the relevance of these processes to the in vivo suppression of T cell lymphoproliferation remains to be identified. The combination of the established mechanisms leading to post-MV infection immunosuppression, and those that remain to be elucidated, cause, in select individuals, severe and on occasion, fatal secondary infection with other microbes.A key epidemiologic factor in measles-related deaths is vitamin A deficiency. In the developing world, the World Health Organization recommends vitamin A supplementation. Studies have demonstrated improved outcomes and suggest an effect on the mucosal barrier and also on improved T cell function though by an undefined mechanism.Read full chapterView PDFRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B9780128167687000491MeaslesWilliam J. Moss, ... W. Harry Feinstone, in Vaccines for Biodefense and Emerging and Neglected Diseases, 2009Measles VirusMeasles virus is a spherical, nonsegmented, single-stranded, negative-sense RNA virus and a member of the Morbillivirus genus in the family of Paramyxoviridae. Other members of the Morbillivirus genus are rinderpest virus and canine distemper virus. Although RNA viruses have high mutation rates, measles virus is an antigenically monotypic virus, meaning that the surface proteins responsible for inducing protective immunity have retained their antigenic structure. The public health significance is that measles vaccines developed decades ago from a single measles virus strain remain protective worldwide. Measles virus is killed by ultraviolet light and heat. Attenuated measles vaccine viruses retain these characteristics, necessitating a cold chain for transportation and storage.The measles virus RNA genome consists of approximately 16,000 nucleotides and is enclosed in a lipid-containing envelope derived from the host cell. The genome encodes eight proteins, two of which (V and C) are nonstructural proteins and are transcribed from the phosphoprotein (P) gene. Of the six structural proteins, P, large protein (L), and nucleoprotein (N) form the nucleocapsid housing the viral RNA. The hemagglutinin protein (H), fusion protein (F), and matrix protein (M), together with lipids from the host cell membrane, form the viral envelope.The H protein interacts with F to mediate fusion of the viral envelope with the host cell membrane (Malvoisin and Wild, 1993). The primary function of the H protein is to bind to the host cellular receptors for measles virus. The two identified receptors are CD46 and CD150 (SLAM). CD46 is a complement regulatory molecule expressed on all nucleated cells in humans. SLAM, an acronym for signaling lymphocyte activation molecule, is expressed on activated T and B lymphocytes and antigen-presenting cells. The binding sites on H for these receptors overlap and strains of measles virus differ in the efficiency with which each is used. Wild-type measles virus binds to cells primarily through the cellular receptor SLAM whereas most vaccine strains bind to CD46; however, most measles virus strains can use both CD46 and SLAM as receptors during acute infection (Schneider et al., 2002). Additional, as yet unidentified receptors for measles virus exist on human endothelial and epithelial cells (Andres et al., 2003).Other measles virus proteins are involved in viral replication. The P protein regulates transcription, replication, and the efficiency with which the N assembles into nucleocapsids (Spehner et al., 1997). The M protein links ribonucleoproteins with envelope proteins during virion assembly. The functions of V and C proteins have not been clearly defined, but both appear to contribute to the virulence of measles virus by regulating transcription and sensitivity to the antiviral effects of interferon (IFN) α/β (Valsamakis et al., 1998; Patterson et al., 2000).Variability within the genome is sufficient to allow for molecular epidemiologic investigation. Genetic characterization of wild-type measles viruses is based on sequence analysis of the genes encoding the N and H proteins. One of the most variable regions of the measles virus genome is the 450-nucleotide sequence at the carboxy-terminal of the N protein, with up to 12% variability between wild-type viruses. The World Health Organization (WHO) recognizes 8 clades of measles virus (designated A through H) and 23 genotypes (World Health Organization, 2006). New genotypes likely will be identified with enhanced surveillance and molecular characterization. As measles control efforts intensify, molecular surveillance of circulating measles virus strains can be used to document interruption of measles virus transmission and to identify the source and transmission pathways of measles virus outbreaks (Rota and Bellini, 2003). Molecular epidemiologic tools also would be important in documenting deliberate bioterrorist introductions of wild-type or genetically modified measles virus strains.Read full chapterView PDFRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B9780123694089000305Viruses as Infectious Agents: Human and Animal VirusesRoberto Cattaneo, Michael McChesney, in Encyclopedia of Virology (Fourth Edition), 2021Life CycleMeV begins its circuit through selected organs of the human body within alveolar macrophages and dendritic cells (DC), which express the primary receptor SLAM. These cells first transfer the infection through the epithelial barrier, and then spread it into lymphoid tissues (Fig. 4, left panel). SLAM was originally identified on activated B and T lymphocytes, but it is also expressed constitutively on immature thymocytes, memory T cells, and certain B cells. Subsets of other cell types, including monocytes and DC, also express SLAM. This cellular distribution overlaps with the susceptibility of different cell types to wild-type MeV infection. Another strong argument for the central role of SLAM in MeV tropism is the fact that three morbilliviruses (MeV, canine distemper virus, and rinderpest virus) enter cells via SLAM (human, canine, or bovine, respectively). Experiments in macaques revealed that the earliest target cells after intratracheal MeV inoculation are DCs and alveolar macrophages.More recently nectin-4, also called poliovirus receptor-like-4 (PVRL4), was shown to serve as the receptor for MeV spread in the upper airway epithelium (Fig. 4, right panel). This adherens junction protein interacts with H with five times higher affinity than SLAM. Nectin-4 sustains basolateral entry of MeV, and of all animal morbilliviruses examined, into upper airway epithelial cells, including those of the trachea.Contrary to the infections with other respiratory viruses, MeV enters the airway epithelium “en masse”: several days after host-to-host transmission, highly infected immune cells synchronously deliver large amounts of virus to the upper airways, for secondary amplification. Since the upper airways are the anatomical location most useful to support particle aerosolization, this two-phase mechanism of host invasion may account for the extremely contagious nature of MeV infection.The live attenuated MeV vaccine strain, Edmonston, can also use the regulator of complement activation membrane cofactor protein (MCP; CD46) as a receptor. The primary function of CD46 is to bind and promote inactivation of the C3b and C4b complement products, a process protecting human cells from lysis by autologous complement, a function that requires ubiquitous expression. Only tissue-culture adapted MeV interact with CD46, and indiscriminate cell entry through this protein correlates with MeV attenuation. A chimeric MeV expressing a vaccine strain H protein, which binds to CD46, is attenuated in the nonhuman primate, and productive infection is still confined to SLAM-expressing cells in vivo.View chapterPurchase bookRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B9780128096338215069Rubeola VirusYvonne A. Maldonado, Avinash K. Shetty, in Principles and Practice of Pediatric Infectious Diseases (Fifth Edition), 2018Description of the PathogenMeasles virus (MV) is an enveloped, nonsegmented, negative-strand RNA virus belonging to the Morbillivirus genus in the Paramyxoviridae family. MV is closely related to rinderpest virus, a cattle pathogen that was eradicated in 2011.6 MV genome consists of 15,894 nucleotides and encodes eight proteins.7 The surface envelope glycoproteins and the hemagglutinin (H) and fusion (F) proteins are the main targets for development of neutralizing antibodies.8 The matrix (M) protein is important in virus assembly. The internal proteins, nucleoprotein (NP), polymerase phosphoprotein (P), and large protein (L), form the nucleocapsid. Two nonstructural proteins (C and V) regulate the cellular response to infection.7The receptor binding H protein interacts with F protein and mediates virus attachment and host cell entry. The F protein enhances cell-to-cell spread of the virus. Neutralizing antibodies are primarily directed against the H protein and confer lifelong immunity.8 There are three identified cellular entry receptors for MV. Human signaling lymphocyte activation molecule (i.e., hSLAM or CD150) is a common immune cell receptor for all MV strains, whereas membrane cofactor protein (i.e., MCP or CD46) is a receptor for vaccine strains.9 A third receptor, poliovirus receptor–like 4 (i.e., PVRL4 or Nectin 4) is expressed on the adherens junctions of epithelial cells.10Wild-type MV infects only primates. Although MV is a monotypic virus, minor genetic and antigenic variation occurs in some virus strains.11 These antigenic variations have not compromised long-lasting immunity. MV is inactivated by lipid solvents, heat, and light.View chapterPurchase bookRead full chapterURL: https://www.sciencedirect.com/science/article/pii/B9780323401814002279
No comment yet.
Scooped by Gilbert C FAURE
March 5, 2022 9:58 AM
Scoop.it!

Vaccines | Free Full-Text | Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial

Vaccines | Free Full-Text | Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial | Mucosal Immunity | Scoop.it
Background: Shigella spp. and enterotoxigenic Escherichia coli (ETEC) cause high morbidity and mortality worldwide, yet no licensed vaccines are available to prevent corresponding infections. A live attenuated non-invasive Shigella vaccine strain lacking LPS O-antigen and expressing the ETEC...
No comment yet.
Scooped by Gilbert C FAURE
March 4, 2022 10:57 AM
Scoop.it!

Frontiers | Bacterial Species Associated With Human Inflammatory Bowel Disease and Their Pathogenic Mechanisms | Microbiology

Frontiers | Bacterial Species Associated With Human Inflammatory Bowel Disease and Their Pathogenic Mechanisms | Microbiology | Mucosal Immunity | Scoop.it
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract with unknown etiology. The pathogenesis of IBD results from immune responses to microbes in the gastrointestinal tract.
No comment yet.
Scooped by Gilbert C FAURE
March 2, 2022 10:30 AM
Scoop.it!

The gut–meningeal immune axis: Priming brain defense against the most likely invaders | Journal of Experimental Medicine | Rockefeller University Press

The vasculature of the meninges contains fenestrated endothelium conferring vulnerability to invasion by circulating microbes, often arising from the gut. Here,
No comment yet.
Scooped by Gilbert C FAURE
March 1, 2022 11:53 AM
Scoop.it!

Frontiers | Establishment of a 3-Dimensional Intestinal Cell Model to Simulate the Intestinal Mucosal Immune System for Food Allergy Investigations | Immunology

Frontiers | Establishment of a 3-Dimensional Intestinal Cell Model to Simulate the Intestinal Mucosal Immune System for Food Allergy Investigations | Immunology | Mucosal Immunity | Scoop.it
Food allergy is a worldwide food safety problem with increasing prevalence. Developing novel approaches for food allergy investigations is the basis for controlling food allergies. In this work, a 3-dimensional (3D) intestinal cell model was established to simulate the intestinal mucosal immune...
No comment yet.
Scooped by Gilbert C FAURE
February 21, 2022 1:08 PM
Scoop.it!

A proximal-to-distal survey of healthy adult human small intestine and colon epithelium by single-cell transcriptomics

A proximal-to-distal survey of healthy adult human small intestine and colon epithelium by single-cell transcriptomics | Mucosal Immunity | Scoop.it
We present a single-cell transcriptomic atlas of epithelial cells from duodenum to
descending colon using three intact healthy adult organs. Thorough analyses provide
differentially expressed/functional genes, regional differences, murine-model comparisons,
and gene sets highlighting potential receptor-ligand and drug target interactions
No comment yet.